Biomea Fusion (NASDAQ:BMEA) Stock, Quote.Headers.trade-ideas

BIOMEA FUSION INC

Biomea Fusion

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

BMEA

Biotech

News

Health Care

Movers

Trading Ideas

General

Biomea Fusion&#39;s COVALENT-111 study shows icovamenib reduces HbA1c significantly in T2D patients, with no safety concerns or drug interactions.

Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?

Earnings

Markets

ALAB

ALTM

ARRY

CHWY

GTLB

HELE

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

LAZR

NCLH

SGML

SMCI

Arcadium Lithium, Norwegian Cruise Line, GitLab, Chewy And Other Big Stocks Moving Higher On Wednesday

investor charts ai2

Pre-Market Outlook

CAPR

IGMS

PMTS

UXIN

IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

Biomea Fusion Inc

Press Releases

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

Biomea Fusion to Become a Diabetes & Obesity Medicines Company

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

Biomea Fusion, Inc. Reports Inducement Grant under  Nasdaq Listing Rule 5635(c)(4)

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Anixa Biosciences

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Atossa Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Coya Therapeutics

Caribou Biosciences

CervoMed

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Fate Therapeutics

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Immunic

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Nkarta

OncoCyte

Regulus Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

TScan Therapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Tenaya Therapeutics

Vor Biopharma

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

XBiotech

Zura Bio Limited - Class A Ordinary shares

Zura Bio

D. Boral Capital

HC Wainwright & Co.

Piper Sandler

EF Hutton

Barclays

Comments

Biomea Fusion

Biomea Fusion (NASDAQ:BMEA) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga